Drug intelligence / Profile preview

SV104

Development stage: Preclinical
Lead developer: Sysvax
Administration: Intradermal

Overview

SV104 is a Purified Protein Derivative (PPD) diagnostic reagent under development by Sysvax for the detection of brucellosis. Brucellosis is a bacterial zoonosis caused by members of the genus *Brucella*. The reagent is composed of a refined mixture of soluble proteins obtained from *Brucella* cultures that have been heat-killed and filtered. When administered, typically via intradermal injection, it triggers a delayed-type hypersensitivity (DTH) reaction in individuals previously sensitized to *Brucella* antigens, serving as a diagnostic indicator of infection. SV104 is currently in preclinical development and is likely intended as a companion diagnostic for human brucellosis screening and vaccine monitoring.

Other names: Brucellosis PPD diagnostic reagent

Beyond the preview

Go deeper on SV104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SV104.

Explore the full profile